FDA Reviewer Backs J&J's Xarelto For Heart Condition
A clinical reviewer for the U.S. Food and Drug Administration recommended that Johnson & Johnson and Bayer AG blood thinner Xarelto be approved for patients with acute coronary syndrome, despite concerns...To view the full article, register now.
Already a subscriber? Click here to view full article